Meet Zetta Genomics – A Fast-Scaling Genomic Data Technology Company

Listen to this article

Below is our recent interview with Mark Bailey, Chief Executive Officer at Zetta Genomics:

Q: Could you provide our readers with a brief introduction to your company?  

A: Zetta Genomics unleashes the power of precision medicine to improve health outcomes for millions of patients around the world.

Founded in 2017, Zetta Genomics is a fast-scaling genomic data technology company headquartered in Cambridge, UK, with offices in Valencia, Spain. A spin-out from the University of Cambridge and Genomics England, Zetta Genomics concentrates genomic, big data and start-up expertise to deliver data management fit for the precision medicine era. 

Q: Any highlights on your recent announcement?   

A: Zetta Genomics, has secured £1.9 million in a second seed funding round. New investment comes from existing VC backers as the company configures for Series A funding. Lead investor Nina Capital is joined by APEX Ventures and Cambridge Enterprise, the innovation arm of the University of Cambridge. The funding round exceeded Zetta’s initial ask, showing the excitement building around the company’s XetaBase platform. 

Recommended: Shannon Global Energy Solutions Engineers And Manufactures Thermal, Acoustic And Safety Insulation Blankets And Shields For Equipment

Q: Can you give us more insights into your offering? 

A: The XetaBase genomic data management platform simplifies tertiary genomic data analysis – aggregating, indexing and enriching secondary data at scale and speed – to accelerate discovery, diagnosis and the delivery of genomic medicine.  

Q: What can we expect from your company in next 6 months? What are your plans? 

A: Our seed funding exceeded our initial ask, showing the excitement building around Zetta Genomics’ game changing XetaBase data analytics platform. We now have the strategic headroom to configure for growth – to scale our technologies, enhance customer focus, and create a cycle of ongoing product innovation. This investment sees us one step closer to realising predictive, precision genomics – transforming research, healthcare and the lives of millions.

Recommended: An Interview With Kati Kleber, Chief Executive Officer At FreshRN

Q: What is the best thing about your company that people might not know about? 

A: In just the last 13 months, Zetta Genomics has expanded genomes under management in its XetaBase platform to over 120,000. The company’s goal is to more than quadruple this to 500,000 genomes under management by the end of 2024.  

  • Reading time:4 mins read
  • Post category:News